Welcome to the NEIAA clinician website

New Resource: Standard Responses to Referrals and Requests for Specialist Advice

National Data Opt-out (NDO) Update

The National Early Inflammatory Arthritis Audit (NEIAA) is no longer exempt from the National Data Opt-out (NDO), as of 7 July 2023. Clinical teams must now check each patient's NDO status before submitting any confidential patient data into the audit. Further information can be found here.

Resources have been compiled by NHS Digital to support with NDO compliance, these can be found here.

Patient Eligibility From 1 April 23

Patient eligibility within the audit has changed from 1 April 23. Patients should now only be entered into the audit when they have a confirmed diagnosis of EIA (Rheumatoid arthritis, Psoriatic arthritis, Axial spondyloarthropathy, Undifferentiated inflammatory arthritis). Year 4 data suggests this will result in a 65% reduction in data burden. In addition to this, patients with confirmed diagnosis of CTD and Systemic Vasculitis, a full list of diagnosis are listed here

CTD:
Systemic lupus erythematosus
Primary Sjogren’s syndrome
Systemic sclerosis
Idiopathic inflammatory myopathy
Undifferentiated/other connect tissue disease or overlap syndrome

Systemic Vasculitis:
Giant cell arteritis
Large vessel vasculitis (not giant cell arteritis)
Anti-neutrophil cytoplasmic antibody-associated vasculitis
Small/medium vessel vasculitis (anti-neutrophil cytoplasmic antibody-negative)
Behçet’s syndrome

There is more information about the changes to data collection here: Changes to The National Early Inflammatory Arthritis Audit (rheumatology.org.uk).

If you have any questions about these changes, please contact the team at audit@rheumatology.org.uk.